2023 Global Cell Surface Testing Market: US, Europe, Japan-2022 Supplier Shares and 2022-2027 Segment Forecasts by Test and Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities for Suppliers
The use of surface marker identification and classification of cells is spreading beyond lymphocytes to the identification of monocytes, macrophages, myeloid stem cells, and tumor cells. A synergistic combination of the hybridoma technology with flow cytometry is further expanding the applications of both technologies. During the next five years, the main trend in cell surface marker analysis will be further simplification of the sample preparation and the analysis itself.
This report presents a detailed overview of the CD4, CD8 and CD34 Cell Surface Marker testing in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice, as well as a 5-year test volume forecasts by country and market segment.
The report examines market applications of monoclonal antibodies, IT, DNA probes, biochips/microarrays, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.
This report presents a detailed overview of the CD4, CD8 and CD34 Cell Surface Marker testing in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice, as well as a 5-year test volume forecasts by country and market segment.
The report examines market applications of monoclonal antibodies, IT, DNA probes, biochips/microarrays, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.
I. INTRODUCTION
II. WORLDWIDE @MARKET AND TECHNOLOGY OVERVIEW
A. Lymphocyte Subclassification CD4/CD8
Instrumentation and Reagent Test Kits
* BD
* Beckman Coulter/Danaher
* T Cells Diagnostics
B. CD34
C. Other Cell Markers
D. Instrumentation Review
1. Hematology Analyzers
a. Overview
Electrical Aperture-Impedance Analyzers
Light Scatter Analyzers
b. System Review
Abbott
Beckman Coulter/Danaher
Biocode Hycel
Drew-Scientific
Horiba
Menarini
Nihon Kohden
Siemens Healthineers
Sysmex
2. Flow Cytometers
a. Introduction
b. System Overview
Becton Dickinson
Beckman Coulter/Danaher
E. Current Market Needs and Future Demand
For Hematology Analyzers
F. Reagents and Controls
G. Current and Emerging Technologies
1. Information Technologies
2. Automation and Robotics
3. Lasers
4. Artificial Intelligence
5. Monoclonal Antibodies
6. Molecular Diagnostics
7. Microdrop Technology
III. FRANCE : FORECASTS BY TEST AND MARKET SEGMENT
IV. GERMANY : FORECASTS BY TEST AND MARKET SEGMENT
V. ITALY : FORECASTS BY TEST AND MARKET SEGMENT
VI. JAPAN : FORECASTS BY TEST AND MARKET SEGMENT
VII. SPAIN : FORECASTS BY TEST AND MARKET SEGMENT
VIII. U.K. : FORECASTS BY TEST AND MARKET SEGMENT
IX. U.S. : FORECASTS BY TEST AND MARKET SEGMENT
X. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for the Decentralized Testing Markets
1. Four Marketing Approaches
2. Product Complexity Factor
3. Customer Preference Factor
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation Factor
XI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
XII. COMPETITIVE ASSESSMENTS
Abbott
Agilent Technologies
Beckman Coulter/Danaher
Becton Dickinson
Bio-Rad
CellaVision
Horiba
Nihon Kohden
Ortho-Clinical Diagnostics
Roche
Siemens Healthineers
Sysmex
XIII. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH
Centers Developing Hematology/Flow Cytometry
Technologies and Applications
II. WORLDWIDE @MARKET AND TECHNOLOGY OVERVIEW
A. Lymphocyte Subclassification CD4/CD8
Instrumentation and Reagent Test Kits
* BD
* Beckman Coulter/Danaher
* T Cells Diagnostics
B. CD34
C. Other Cell Markers
D. Instrumentation Review
1. Hematology Analyzers
a. Overview
Electrical Aperture-Impedance Analyzers
Light Scatter Analyzers
b. System Review
Abbott
Beckman Coulter/Danaher
Biocode Hycel
Drew-Scientific
Horiba
Menarini
Nihon Kohden
Siemens Healthineers
Sysmex
2. Flow Cytometers
a. Introduction
b. System Overview
Becton Dickinson
Beckman Coulter/Danaher
E. Current Market Needs and Future Demand
For Hematology Analyzers
F. Reagents and Controls
G. Current and Emerging Technologies
1. Information Technologies
2. Automation and Robotics
3. Lasers
4. Artificial Intelligence
5. Monoclonal Antibodies
6. Molecular Diagnostics
7. Microdrop Technology
III. FRANCE : FORECASTS BY TEST AND MARKET SEGMENT
IV. GERMANY : FORECASTS BY TEST AND MARKET SEGMENT
V. ITALY : FORECASTS BY TEST AND MARKET SEGMENT
VI. JAPAN : FORECASTS BY TEST AND MARKET SEGMENT
VII. SPAIN : FORECASTS BY TEST AND MARKET SEGMENT
VIII. U.K. : FORECASTS BY TEST AND MARKET SEGMENT
IX. U.S. : FORECASTS BY TEST AND MARKET SEGMENT
X. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for the Decentralized Testing Markets
1. Four Marketing Approaches
2. Product Complexity Factor
3. Customer Preference Factor
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation Factor
XI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
XII. COMPETITIVE ASSESSMENTS
Abbott
Agilent Technologies
Beckman Coulter/Danaher
Becton Dickinson
Bio-Rad
CellaVision
Horiba
Nihon Kohden
Ortho-Clinical Diagnostics
Roche
Siemens Healthineers
Sysmex
XIII. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH
Centers Developing Hematology/Flow Cytometry
Technologies and Applications
LIST OF TABLES
France, Hospital Laboratories Estimated
Cell Surface Marker Test Volume
France, Commercial/Private Laboratories Estimated
Cell Surface Marker Test Volume
Germany, Hospital Laboratories Estimated
Cell Surface Marker Test Volume
Italy, Hospital Laboratories Estimated
Cell Surface Marker Test Volume
Italy, Commercial/Private Laboratories Estimated
Cell Surface Marker Test Volume
Japan, Hospital Laboratories Estimated
Cell Surface Marker Test Volume
Japan, Commercial/Private Laboratories Estimated
Cell Surface Marker Test Volume
Spain, Hospital Laboratories Estimated
Cell Surface Marker Test Volume
Spain, Commercial/Private Laboratories Estimated
Cell Surface Marker Test Volume
Spain, Ambulatory Care Center Estimated
Cell Surface Marker Test Volume
U.K., Hospital Laboratories Estimated
Cell Surface Marker Test Volume
U.K., Commercial/Private Laboratories Estimated
Cell Surface Marker Test Volume
U.S., Hospital Laboratories Estimated
Cell Surface Marker Test Volume
U.S., Commercial/Private Laboratories Estimated
Cell Surface Marker Test Volume
U.S., Physician Office Laboratories Estimated
Cell Surface Marker Test Volume
France, Hospital Laboratories Estimated
Cell Surface Marker Test Volume
France, Commercial/Private Laboratories Estimated
Cell Surface Marker Test Volume
Germany, Hospital Laboratories Estimated
Cell Surface Marker Test Volume
Italy, Hospital Laboratories Estimated
Cell Surface Marker Test Volume
Italy, Commercial/Private Laboratories Estimated
Cell Surface Marker Test Volume
Japan, Hospital Laboratories Estimated
Cell Surface Marker Test Volume
Japan, Commercial/Private Laboratories Estimated
Cell Surface Marker Test Volume
Spain, Hospital Laboratories Estimated
Cell Surface Marker Test Volume
Spain, Commercial/Private Laboratories Estimated
Cell Surface Marker Test Volume
Spain, Ambulatory Care Center Estimated
Cell Surface Marker Test Volume
U.K., Hospital Laboratories Estimated
Cell Surface Marker Test Volume
U.K., Commercial/Private Laboratories Estimated
Cell Surface Marker Test Volume
U.S., Hospital Laboratories Estimated
Cell Surface Marker Test Volume
U.S., Commercial/Private Laboratories Estimated
Cell Surface Marker Test Volume
U.S., Physician Office Laboratories Estimated
Cell Surface Marker Test Volume
More Publications
2016-2020 France Transfusion Analyzers and Consumables Market: Molecular Blood Typing, Grouping and Infectious Disease NAT/Nucleic Acid Testing- Supplier Shares, Country Segment Forecasts for over 40 Tests, Strategies, Technologies, Instrumentation
US$ 4,880.00
March 2016
435 pages
2016-2020 Emerging Molecular Diagnostic Technologies and Strategic Profiles of Leading Suppliers
US$ 3,080.00
March 2016
185 pages
Global Suppliers of Immunodiagnostic, Microbiology, Cancer Diagnostic, Molecular Diagnostic, Hematology, Coagulation and Blood Banking Analyzers and Reagents
US$ 4,750.00
June 2019
200 pages
2019-2023 Molecular Diagnostics Market: Supplier Shares, Sales Forecasts and Facilities by Country
US$ 2,450.00
February 2019
15 pages
2015 Strategies in the US Hospital Hematology and Flow Cytometry Market
US$ 5,440.00
February 2015
248 pages